Seattle Genetics, Inc. CEO Not Interested in a Sale

Seattle Genetics Inc. (SGEN) (SGEN) Chief Executive Officer Clay Siegall says he has a model for growth of the biotechnology company’s only drug, cancer treatment Adcetris: Roche Holding AG (ROG)’s $6.7 billion-seller Rituxan. Adcetris received U.S. clearance in August for use by Hodgkin’s lymphoma patients who failed on other therapies, a smaller market than the front-line treatment the company aims for after added trials are completed in the next few years. Rituxan, approved as an initial treatment for lymphoma in 1997, took a similar path, Siegall said in a telephone interview.